Published On: Fri, Nov 14th, 2014

Israeli Company’s Bone Marrow Transplant Drug Approved for Human Testing

Cell Source

Israel’s Cell Source Inc., an immunotherapy and regenerative medicine company, announced that its Megadose Drug Combination which assists in bone marrow transplants has been cleared for human clinical trials in Italy.

Cell Source’s expects that its proprietary Megadose Drug Combination will increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT.

BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure’s use may well be expanded beyond cancer to other indications including genetic and autoimmune disease.

In preclinical studies Megadose Drug Combination has shown success in inducing immune tolerance. The drug has shown to enable the coexistence of host and donor DNA, thus significantly reducing transplant rejection.
Cell Source is the exclusive worldwide licensee of a variety of progressive cell therapy technologies invented at the Weizmann Institute of Science, one of Israel’s and the world’s leading research institutes.

A leading Italian university hospital with extensive BMT experience, an independent third party organization, has on its own initiative chosen to conduct a human clinical trial of Megadose Drug Combination on a self-directed basis.

The Italian university filed an investigational new drug application (IND) with the Italian Medicine Association, the Italian equivalent of the U.S. FDA, to conduct human clinical trials using the Megadose Drug Combination in the first half of 2014. The Italian Medicine Association granted approval for the IND and commencement of the study with a small number of patients on October 23, 2014.

“We are very pleased that independent researchers at this Italian university have found our Megadose Drug Combination compelling enough to initiate their own study. The treatment protocol the university intends to implement for the study is the same protocol we intend to use in our own future Phase I/II study. Therefore, the data resulting from their study will be an important indicator for Cell Source’s future trials and positive results would serve as an additional springboard, ” stated Cell Source President and CEO Itamar Shimrat.

Read more about: , , , , , , , , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems